Navigation Links
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
Date:5/2/2013

his new treatment option available to patients in additional parts of the world."

APD811 

  • Initiated dosing of an additional cohort in a Phase 1 multiple dose clinical trial of APD811, an oral drug candidate that targets the prostacyclin (IP) receptor for the potential treatment of pulmonary arterial hypertension (PAH). This randomized, double-blind and placebo-controlled trial is designed to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811 and to optimize the dosing regimen prior to potentially initiating a Phase 2 clinical trial.
  • APD334

  • Initiated dosing in a Phase 1 clinical trial of APD334, an oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of various autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1 trial is designed to evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD334.
  • "We are leveraging our validated research and development capabilities to continue to build and advance our pipeline of innovative drug candidates," said William R. Shanahan , M.D., Arena's Senior Vice President and Chief Medical Officer. "With APD811 and APD334, we look forward to potentially expanding the options available to patients and physicians for the treatment of PAH and certain autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and psoriasis."

    First Quarter 2013 Financial Results Arena recognized revenues totaling $2.4 million in the first quarter of 2013, compared to $2.2 million in the first quarter of 2012. The revenue recognized in 2013 includes a $500,000 milestone payment earned from Eisai upon filing the BELVIQ MAA in Mexico.

    Research and development expenses in the first quarter of 2013 decreased to $14.0 million, compared to $14.5 million in the f
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
    2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
    3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
    4. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
    5. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
    6. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
    7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
    8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
    9. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
    10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
    11. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... , Aug. 31, 2015  Regulatory affairs professionals ... where regulations are often strict and legislation is ... a demand for professionals who have a deep ... across a product lifecycle and demonstrate its use ... University of California, Irvine Extension , in partnership ...
    (Date:8/31/2015)... 2015  Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Hagerman , Chairman & CEO, and Sean Whelan , ... Mr. Hagerman and Mr. Whelan are scheduled to participate ... Boston on Wednesday, September 9, 2015 at 1:45 ... also scheduled to participate in the Robert W. Baird 2015 ...
    (Date:8/31/2015)... Aug. 31, 2015  Qualcomm Incorporated (NASDAQ: ... Qualcomm Life, Inc., is collaborating with Davita ... management solutions powered by Qualcomm Life,s 2net™ Device ... enable continuous care, informed interventions and better management ... Qualcomm Life,s annual Connect 2015 ecosystem ...
    Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
    ... 2011 First Quarter Total Revenue $565 million, including $36 million ... growth for the combined company, excluding the impact of foreign exchange ... Diastat and Efudex, pro forma organic growth for the combined company ... EPS $0.02; Cash EPS $0.62 Excluding impact from ...
    ... 9, 2011 Medison and Samsung Electronics jointly announced ... company, a joint partnership between Korea,s leading diagnostic ultrasound ... most technologically-advanced electronics and consumer goods companies, has outlined ... leader in medical device industry. Mr. ...
    Cached Medicine Technology:Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 2Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 3Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 4Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 5Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 6Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 7Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 8Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 9Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 10Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 11Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 12Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 13Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results 14Samsung Medison Pledges to Become a World-Class Medical Device Company 2
    (Date:8/31/2015)... Lisle, IL (PRWEB) , ... August 31, 2015 , ... ... announce that Firm Partner William Scott has been nominated by his peers to earn ... by less than five percent of attorneys in the state of Illinois. The nomination ...
    (Date:8/31/2015)... , ... August 31, 2015 , ... ... Vice President, Marketing and Corporate Communications. In this capacity, Michael will provide strategic ... is an industry leader in consumer-focused programs that have contributed to the company’s ...
    (Date:8/31/2015)... Newton, North Carolina (PRWEB) , ... August 31, 2015 , ... ... Abernethy Laurels on Tuesday, September 1. , “Alive Inside” shadows a social ... nonprofit “MUSIC & MEMORY?.” , “It’s a documentary about bringing music to residents in ...
    (Date:8/31/2015)... ... August 31, 2015 , ... David L. ... was one of the first doctors in the area to perform minimally invasive ... have been impressive: faster recovery, decreased immediate and long-term pain, and an accelerated ...
    (Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... With the FCPX LUT Soft pack from ... LUT is a Lookup Table that contains a mathematical formula for modifying an image. The ... comes with 60 soft CUBE LUT files. , FCPX LUT Soft requires Final Cut ...
    Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2
    ... Leading patient safety software company to team up ... CAMBRIDGE, MA, Aug. 19 /PRNewswire/ - rL Solutions, the leading ... it will become the founding Corporate Alliance Sponsor of the ... Association. , As part of the partnership, rL Solutions will ...
    ... , SOMERSET, N.J., Aug. 19 The Tic ... Care (R), it will try to break the Guinness World Record(TM) in ... for charity. Cancer C are is a national nonprofit ... , , Starting today at 11 a.m. ET, individuals ...
    ... ... a successful strategic workforce planning process,” stated Jim Sirbasku, co-founder and CEO of Profiles ... provides guidelines for implementing each of those 6 components.” , ... Waco, TX (PRWEB) August 19, 2009 -- ...
    ... ... LLP is urging the manufacturers of the fentanyl or Duragesic pain patches ... potentially fatal overdose. Because of its high potency, patients who receive too much ... a fentanyl overdose. Watson Pharmaceuticals recalled one lot of its fentanyl patches on ...
    ... ... a group of dentists emphasizing the urgent need for dentists to screen patients for snoring ... , ... Dr. Laurence Barsh recently spoke at the first annual Somnomed Symposium in Oahu, HI to ...
    ... allows physicians to evaluate suspicious lesions using a variety ... information can help significantly in distinguishing benign from malignant ... published in the September issue of the American ... the study, performed at the University of Washington Medical ...
    Cached Medicine News:Health News:rL Solutions to Become the Founding Corporate Alliance Sponsor of the Society for Healthcare Consumer Advocacy 2Health News:CancerCare(R) and the Tic Tac(R) Brand Attempt To Set a World Record in Times Square 2Health News:CancerCare(R) and the Tic Tac(R) Brand Attempt To Set a World Record in Times Square 3Health News:Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning 2Health News:Hissey Kientz, LLP Warns Duragesic Patch Users about Potential Health Risks of Fentanyl Overdose 2Health News:Hissey Kientz, LLP Warns Duragesic Patch Users about Potential Health Risks of Fentanyl Overdose 3Health News:Laurence Barsh, DMD, Founder of Snoring Isn't Sexy, LLC Emphasizes Need to Evaluate and Treat Sleep Patients 2
    For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
    ZyDoc offers a full medical transcription and documentation solution....
    For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
    For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
    Medicine Products: